5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Various phenotypes of LRBA gene with compound heterozygous variation: A case series report of pediatric cytopenia patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective:

          LPS-responsive beige-like anchor (LRBA) deficiency is one of the most common monogenic disorders causing common variable immunodeficiency (CVID) and CVID-like disorders. However, the clinical spectrum of compound heterozygous (CHZ) LRBA variation should be extended. In this study, we presented five cases of compound heterozygous LRBA with various refractory cytopenias.

          Materials and Methods:

          Retrospective analysis of the clinical manifestations, management, and outcomes of five cases (from five pedigrees) with LRBA gene CHZ variants which initially manifested as single/multilineage immune cytopenias was performed.

          Results:

          1. Gene variations: All five patients inherited the compound heterozygous LRBA variations from their parents which were thought to be pathogenic. BEACH, DUF4704, and LamG were the main affected domains of LRBA gene in this case series. 2. Immune dysregulation of clinic: (1) Hypogammaglobulinemia were recorded in four patients, and the proportion of Treg was decreased in two patients. Only one patient had been with increased TCRαβ+CD4/CD8 double-negative T cells (DNT). (2) Lymphoproliferative manifestations were seen in three patients. (3) All five patients were complained with cytopenia, although they showed different clinical manifestations. None of the parents was asymptomatic. (4) Other immune disorders: P5 also had relapsed infections and autoimmune endocrinopathy. 3. Management and outcomes: P1 and P5 responded well to immunomodulatory therapy and P3 was effectively treated with hemophagocytic lymphohistiocytosis (HLH) first-line regimen chemotherapy. P4 showed no responses to steroids and IVIG. However, TPO-R agonist was effective.

          Conclusion:

          Unlike homozygous mutations, compound heterozygous LRBA variation should always be kept in mind for the various phenotypes and different treatment responses.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          mTORC1 couples immune signals and metabolic programming to establish Treg cell function

          The mechanistic target of rapamycin (mTOR) pathway integrates diverse environmental inputs, including immune signals and metabolic cues, to direct T cell fate decisions 1 . Activation of mTOR, comprised of mTORC1 and mTORC2 complexes, delivers an obligatory signal for proper activation and differentiation of effector CD4+ T cells 2,3 , whereas in the regulatory T cell (Treg) compartment, the Akt-mTOR axis is widely acknowledged as a crucial negative regulator of Treg de novo differentiation 4–8 and population expansion 9 . However, whether mTOR signaling affects the homeostasis and function of Tregs remains largely unexplored. Here we show that mTORC1 signaling is a pivotal positive determinant of Treg function. Tregs have elevated steady-state mTORC1 activity compared to naïve T cells. Signals via T cell receptor (TCR) and IL-2 provide major inputs for mTORC1 activation, which in turn programs suppressive function of Tregs. Disruption of mTORC1 through Treg-specific deletion of the essential component Raptor leads to a profound loss of Treg suppressive activity in vivo and development of a fatal early-onset inflammatory disorder. Mechanistically, Raptor/mTORC1 signaling in Tregs promotes cholesterol/lipid metabolism, with the mevalonate pathway particularly important for coordinating Treg proliferation and upregulation of suppressive molecules CTLA-4 and ICOS to establish Treg functional competency. In contrast, mTORC1 does not directly impact the expression of Foxp3 or anti- and pro-inflammatory cytokines in Tregs, suggesting a non-conventional mechanism for Treg functional regulation. Lastly, we provide evidence that mTORC1 maintains Treg function partly through inhibiting the mTORC2 pathway. Our results demonstrate that mTORC1 acts as a fundamental ‘rheostat’ in Tregs to link immunological signals from TCR and IL-2 to lipogenic pathways and functional fitness, and highlight a central role of metabolic programming of Treg suppressive activity in immune homeostasis and tolerance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.

            Mutations in the LRBA gene (encoding the lipopolysaccharide-responsive and beige-like anchor protein) cause a syndrome of autoimmunity, lymphoproliferation, and humoral immune deficiency. The biological role of LRBA in immunologic disease is unknown. We found that patients with LRBA deficiency manifested a dramatic and sustained improvement in response to abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)-immunoglobulin fusion drug. Clinical responses and homology of LRBA to proteins controlling intracellular trafficking led us to hypothesize that it regulates CTLA4, a potent inhibitory immune receptor. We found that LRBA colocalized with CTLA4 in endosomal vesicles and that LRBA deficiency or knockdown increased CTLA4 turnover, which resulted in reduced levels of CTLA4 protein in FoxP3(+) regulatory and activated conventional T cells. In LRBA-deficient cells, inhibition of lysosome degradation with chloroquine prevented CTLA4 loss. These findings elucidate a mechanism for CTLA4 trafficking and control of immune responses and suggest therapies for diseases involving the CTLA4 pathway.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity.

              Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently not well understood. Most affected individuals are simplex cases, but both autosomal-dominant and autosomal-recessive inheritance have been described. We performed genetic linkage analysis in consanguineous families affected by hypogammaglobulinemia. Four consanguineous families with childhood-onset humoral immune deficiency and features of autoimmunity shared genotype evidence for a linkage interval on chromosome 4q. Sequencing of positional candidate genes revealed that in each family, affected individuals had a distinct homozygous mutation in LRBA (lipopolysaccharide responsive beige-like anchor protein). All LRBA mutations segregated with the disease because homozygous individuals showed hypogammaglobulinemia and autoimmunity, whereas heterozygous individuals were healthy. These mutations were absent in healthy controls. Individuals with homozygous LRBA mutations had no LRBA, had disturbed B cell development, defective in vitro B cell activation, plasmablast formation, and immunoglobulin secretion, and had low proliferative responses. We conclude that mutations in LRBA cause an immune deficiency characterized by defects in B cell activation and autophagy and by susceptibility to apoptosis, all of which are associated with a clinical phenotype of hypogammaglobulinemia and autoimmunity.
                Bookmark

                Author and article information

                Journal
                Int J Immunopathol Pharmacol
                Int J Immunopathol Pharmacol
                spiji
                IJI
                International Journal of Immunopathology and Pharmacology
                SAGE Publications (Sage UK: London, England )
                0394-6320
                2058-7384
                8 September 2022
                Jan-Dec 2022
                : 36
                : 03946320221125591
                Affiliations
                [1 ]Hematology Center, National Center for Children`s Health, Ringgold 117984, universityBeijing Children`s Hospital, Capital Medical University; , Beijing, China
                [2 ]Hematologic Disease Laboratory, National Center for Children’s Health, Ringgold 117984, universityBeijing Children’s Hospital, Capital Medical University; , Beijing, China
                [3 ]Laboratory of Tumor Immunology, National Center for Children’s Health, Ringgold 117984, universityBeijing Children’s Hospital, Capital Medical University; , Beijing, China
                Author notes
                [*]Jin Jiang, Hematologic Disease Laboratory, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, Beijing 100045, China. Email: runhuiwu@ 123456hotmail.com
                [*]Runhui Wu, Hematologic Disease Laboratory, National Center for Children’s Health, Beijing Children’s Hospital, Capital Medical University, No.56 Nanlishi Road, Xicheng District, Beijing 100045, China. Email: jiangjin0325@ 123456163.com
                [†]

                Jiafeng Yao, Hao GU and Wenjun Mou have contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-4278-8559
                Article
                10.1177_03946320221125591
                10.1177/03946320221125591
                9465590
                36074705
                3191c867-a7c3-466b-879b-cbc751ea06da
                © The Author(s) 2022

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                : 26 June 2021
                : 21 September 2021
                Funding
                Funded by: the National Natural Science Foundation of China, FundRef https://doi.org/10.13039/100014717;
                Award ID: 81970111
                Funded by: Beijing Natural Science Foundation of China;
                Award ID: 7192064
                Funded by: National Science and Technology Key Projects;
                Award ID: 2017ZX09304029001
                Funded by: Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority;
                Award ID: No.XTZD20180205
                Categories
                Original Research Article
                Custom metadata
                ts10
                January-December 2022

                lps-responsive beige-like anchor deficiency,common variable immunodeficiency,autoimmune lymphoproliferative syndrome,hypogammaglobulinemia,immunomodulatory therapy

                Comments

                Comment on this article